Condition
Axial Spondyloarthritis (AxSpA) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Axial Spondyloarthritis (AxSpA) clinical trials that are recruiting, at sites in 8 countries (most in Germany (2), Netherlands (2), Australia (1)). By phase: Phase 1/2 (1), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 8Countries
Newest Axial Spondyloarthritis (AxSpA) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Validation of the 2025 Axial Spondyloarthritis Classification Criteria in Chinese patients | — | Beijing, Beijing Municipality | Recruiting | Jul 24, 2026 |
| Lowering JAK inhibitor doses in people with RA, PsA, or axSpA who are in low disease activity or remission | Phase 4 | Nijmegen, Gelderland and 6 other locations | Recruiting | Sep 8, 2025 |
| Oral ERAP1 blocker GRWD0715 for axial spondyloarthritis (EAST-1) | Phase 1/2 | Birtinya and 15 other locations | Recruiting | Jul 2, 2025 |
| Evaluating movement recommendations for patients with axial spondyloarthritis using smartwatches | — | Bonn, North Rhine-Westphalia | Recruiting | Feb 4, 2025 |
| Comparing yoga therapy and physiotherapy for moderate axial spondyloarthritis | — | Bobigny and 4 other locations | Recruiting | Oct 13, 2023 |
All recruiting trials (5)
-
Validation of the 2025 Axial Spondyloarthritis Classification Criteria in Chinese patients
This study tests whether the 2025 ASAS-SPARTAN criteria correctly classify axial spondyloarthritis in adults with chronic back pain in China.
-
Lowering JAK inhibitor doses in people with RA, PsA, or axSpA who are in low disease activity or remission
This study will test whether carefully lowering the dose of Janus kinase inhibitors keeps disease control as well as staying on the same dose in people with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who are in remission or have low disease activity.
-
Oral ERAP1 blocker GRWD0715 for axial spondyloarthritis (EAST-1)
This will test an oral drug called GRWD0715 that blocks the ERAP1 enzyme to see if it is safe and helps people with axial spondyloarthritis, with an early part in healthy adults.
-
Evaluating movement recommendations for patients with axial spondyloarthritis using smartwatches
This study is testing how using smartwatches to track movement can help people with axial spondyloarthritis find better ways to stay active and manage their symptoms.
-
Comparing yoga therapy and physiotherapy for moderate axial spondyloarthritis
This study is testing whether yoga therapy can help people with moderate axial spondyloarthritis feel better compared to traditional physiotherapy.
Related topics
Quick answers
How many Axial Spondyloarthritis (AxSpA) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 8 countries. The most sites are in Germany (2 trials), Netherlands (2 trials), Australia (1 trial), Belgium (1 trial), Poland (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.